ONCOMED PHARMACEUTICALS INC's ticker is OMED and the CUSIP is 68234X102. A total of 56 filers reported holding ONCOMED PHARMACEUTICALS INC in Q1 2014. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2018 | $105,000 | -85.8% | 49,557 | -78.7% | 0.00% | -100.0% |
Q1 2018 | $740,000 | -66.8% | 232,774 | -57.2% | 0.00% | -66.7% |
Q4 2017 | $2,228,000 | +125.5% | 543,335 | +148.7% | 0.00% | +50.0% |
Q3 2017 | $988,000 | +5.0% | 218,490 | -22.7% | 0.00% | 0.0% |
Q2 2017 | $941,000 | -83.8% | 282,665 | -55.2% | 0.00% | -81.8% |
Q1 2017 | $5,807,000 | +138.6% | 630,507 | +99.7% | 0.01% | +120.0% |
Q4 2016 | $2,434,000 | -67.3% | 315,719 | -51.5% | 0.01% | -58.3% |
Q3 2016 | $7,446,000 | +40.8% | 651,473 | +51.6% | 0.01% | 0.0% |
Q2 2016 | $5,290,000 | +1004.4% | 429,693 | +807.4% | 0.01% | +1100.0% |
Q1 2016 | $479,000 | -75.9% | 47,356 | -60.5% | 0.00% | -75.0% |
Q3 2015 | $1,991,000 | +709.3% | 120,000 | +823.0% | 0.00% | +300.0% |
Q3 2014 | $246,000 | -7.5% | 13,001 | +14.0% | 0.00% | 0.0% |
Q2 2014 | $266,000 | -72.5% | 11,400 | -60.4% | 0.00% | -66.7% |
Q1 2014 | $968,000 | +39.1% | 28,760 | -36.7% | 0.00% | +50.0% |
Q3 2013 | $696,000 | – | 45,466 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BVF INC/IL | 4,042,989 | $8,571,000 | 0.75% |
NEXTHERA CAPITAL LP | 634,715 | $1,346,000 | 0.26% |
Endurant Capital Management LP | 219,114 | $465,000 | 0.21% |
Birchview Capital, LP | 118,689 | $252,000 | 0.16% |
Perceptive Advisors | 2,620,897 | $5,556,000 | 0.15% |
Alambic Investment Management, L.P. | 53,972 | $114,000 | 0.09% |
Sofinnova Investments, Inc. | 395,744 | $839,000 | 0.08% |
Kazazian Asset Management, LLC | 31,475 | $67,000 | 0.06% |
Broadfin Capital, LLC | 200,000 | $424,000 | 0.06% |
ESSEX INVESTMENT MANAGEMENT CO LLC | 96,639 | $205,000 | 0.02% |